CONSTANT LEVERAGE SHORT - MODERNA | Market Closed - Euronext Paris 12:30:02 2024-05-16 EDT | ||
| 0.242 EUR | -20.13% |
|
| Current month | -76.68% | ||
| 1 month | -84.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-16 | 0.263 | -13.20% |
| 24-05-15 | 0.303 | +7.83% |
| 24-05-14 | 0.281 | -25.46% |
| 24-05-13 | 0.377 | -22.75% |
| 24-05-10 | 0.488 | +25.45% |
Real-time Euronext Paris
Last update May 16, 2024 at 12:30 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| 4GCNB | |
| ISIN | FRBNPP06ABB4 |
| Date issued | 2024-01-03 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 4.535 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.38 € |
|---|---|
| Lowest since issue | 0.242 € |
| Spread | 0.01 € |
| Spread % | 4.03% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.6
USD
Average target price
138.5
USD
Spread / Average Target
+4.43%
- Stock Market
- Certificates
- 4GCNB Certificat